Immunohistochemical Analysis of Omi/HtrA2 Expression in Prostate Cancer and Benign Prostatic Hyperplasia
- Author:
Xiaoyong HU
1
;
Xiaochun CHEN
;
Hao PING
;
Zhaohui CHEN
;
Fuqing ZENG
;
Gongcheng LU
Author Information
1. 华中科技大学同济医学院附属协和医院
- Keywords:
Omi/HtrA2;
serine protease;
prostate cancer;
benign prostatic hyperplasia;
apoptosis
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2005;25(6):671-673
- CountryChina
- Language:Chinese
-
Abstract:
To study the expression and significance of the serine protease Omi/HtrA2 in prostate cancer and benign prostatic hyperplasia. The expression of Omi/HtrA2 was assayed by means of immunohistochemical technique in 41 prostate cancer (Cap), 20 benign prostatic hyperplasia (BPH) and 10 normal prostate (NP) specimens. Omi/HtrA2 expression was positive in 30 (73.17%) prostate cancer specimens, and the positive rate of Omi/HtrA2 was lower in well differentiated than in poorly and moderately differentiated groups (P＜0.05). By contrast, the cells in normal prostate and benign prostatic hyperplasia groups showed no or weak expression of Omi/HtrA2.Prostate cancer cells in vivo may need Omi/HtrA2 expression for apoptosis, and that Omi/HtrA2expression might be involved in prostate cancer development.
